PROVETOP

Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein

Catalog No: AFP-HP001

Species
Human
Expression System
E. coli
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and FMNKFIYEI peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &FMNKFIYEI).

Product Details

Molecular Aliases
Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA;
Protein Length
Gly25-Thr305
Expression System
E. coli
Theoretical Molecular Weight
The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
AFP-HP001 Bis-Tris-PAGE result

Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
AFP-HP001 SEC-HPLC result

The purity of Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer is greater than 95% as determined by SEC-HPLC.

ELISA
AFP-HP001 ELISA result

Immobilized Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 8.3ng/ml determined by ELISA.

Background

Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.

References

  1. (1) Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17. PMID: 27535982.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support